Table of Content

Table of Content


1. Market Background
1.1 Scope and Product Outlook
1.2 Executive Summary
1.3 Research Methodology


2. Analyst Recommendations
2.1 Augment the availability of combinational drugs
2.2 Escalate Distribution through Online services


3. Global Endometriosis and Uterine Fibroids Market: Historic and Forecast

3.1 Impact Analysis of Macro Economic Factors on Global Endometriosis and Uterine Fibroids Market
3.2 Global Endometriosis and Uterine Fibroids Market: Dashboard
3.3 Global Endometriosis and Uterine Fibroids Market: Market Value Assessment3.4 Regional Snapshot


4. Americas Endometriosis and Uterine Fibroids Market

4.1 Americas Endometriosis and Uterine Fibroids Market: Market Value Assessment
4.2 Americas Endometriosis and Uterine Fibroids Market: Key Factors
4.3 Americas Endometriosis and Uterine Fibroids Market: Segment Analysis
4.4 Americas Endometriosis and Uterine Fibroids Market: By Country Overview


5. United States Endometriosis and Uterine Fibroids Market

5.1 United States Endometriosis and Uterine Fibroids: Dashboard
5.2 United States Endometriosis and Uterine Fibroids: Market Value Assessment
5.3 United States Endometriosis and Uterine Fibroids: By Drug Type
5.3.1 United States Endometriosis and Uterine Fibroids Market, By Drug Type Overview
5.3.2 United States Endometriosis and Uterine Fibroids Market Size, By GnRH Antagonists, By Value, 2020H-2030F (USD Million & CAGR)
5.3.3 United States Endometriosis and Uterine Fibroids Market Size, By Progesterone, By Value, 2020H-2030F (USD Million & CAGR)
5.3.4 United States Endometriosis and Uterine Fibroids Market Size, By GnRH Agonists, By Value, 2020H-2030F (USD Million & CAGR)
5.3.5 United States Endometriosis and Uterine Fibroids Market Size, By Others, By Value, 2020H-2030F (USD Million & CAGR)
5.4 United States Endometriosis and Uterine Fibroids: By Route of Administration
5.4.1 United States Endometriosis and Uterine Fibroids Market, By Route of Administration Overview
5.4.2 United States Endometriosis and Uterine Fibroids Market Size, By Oral, By Value, 2020H-2030F (USD Million & CAGR)
5.4.3 United States Endometriosis and Uterine Fibroids Market Size, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)
5.3.4 United States Endometriosis and Uterine Fibroids Market Size, By Online Pharmacies, By Value, 2020H-2030F (USD Million & CAGR)
5.4 United States Endometriosis and Uterine Fibroids: By Distribution Channel
5.4.1 United States Endometriosis and Uterine Fibroids Market, By Distribution Channel Overview
5.4.2 United States Endometriosis and Uterine Fibroids Market Size, By Hospital Pharmacies, By Value, 2020H-2030F (USD Million & CAGR)
5.4.3 United States Endometriosis and Uterine Fibroids Market Size, By Retail Pharmacies, By Value, 2020H-2030F (USD Million & CAGR)
5.4.4 United States Endometriosis and Uterine Fibroids Market Size, By Online Pharmacies, By Value, 2020H-2030F (USD Million & CAGR)


6. United States Endometriosis and Uterine Fibroids Epidemiology and Pipeline Analysis
6.1 Epidemiology: United States Endometriosis and Uterine Fibroids Prevalence
6.2 Epidemiology: United States Endometriosis and Uterine Fibroids Incidence
6.3 Pipeline Scenario


7. Market Dynamics
7.1 Impact Assessment of Market Dynamics on United States Endometriosis and Uterine Fibroids
7.2 Market Dynamics of United States Endometriosis and Uterine Fibroids: Drivers
7.3 Market Dynamics of United States Endometriosis and Uterine Fibroids: Restraints
7.4 Market Dynamics of United States Endometriosis and Uterine Fibroids: Trends


8. Industry Ecosystem Analysis
8.1 Porter Analysis of United States Endometriosis and Uterine Fibroids Market


9. Competitive Positioning
9.1 Companies Product Positioning
9.2 Market Position Matrix
9.3 Market Share Analysis of United States Endometriosis and Uterine Fibroids Market
9.4 Company Profiles
9.4.1 AbbVie Inc.
9.4.2 Pfizer Inc.
9.4.3 AstraZeneca plc.
9.4.4 Tolmar Inc.
9.4.5 Glenmark Pharmaceuticals Ltd.
9.4.6 Aspen Pharmacare Holdings Ltd.
9.4.7 Agile Therapeutics Inc
9.4.8 Medicines 360
9.4.9 Cipla Ltd
9.4.10 Takeda Pharmaceuticals


10. About us & Disclaimer



List of Figures

List of Figures

Figure 1: United States Endometriosis and Uterine Fibroids Market Size, By Value, 2020-2023 (USD Million)
Figure 2: United States Endometriosis and Uterine Fibroids Market Size, By Value, 2024-2030 (USD Million)
Figure 3: Americas Endometriosis and Uterine Fibroids Market Size, By Value, 2020H-2030F (USD Million)
Figure 4: United States Endometriosis and Uterine Fibroids Market Size, By Value, 2020-2023 (USD Million)
Figure 5: United States Endometriosis and Uterine Fibroids Market Size, By Value, 2024-2030 (USD Million)
Figure 6: United States Endometriosis and Uterine Fibroids Market Share, By Drug Type, 2023 (%)
Figure 7: Market Attractiveness Analysis of United States Endometriosis and Uterine Fibroid Market, By Drug Type (2025-2030)
Figure 8: United States Endometriosis and Uterine Fibroids Market Size, By GnRH Antagonist, By Value, 2020H-2030F (USD Million & CAGR)
Figure 9: United States Endometriosis and Uterine Fibroids Market Absolute Opportunity, By GnRH Antagonist, 2020-2030 (USD Million)
Figure 10: United States Endometriosis and Uterine Fibroids Market Size, By Progesterone, By Value, 2020H-2030F (USD Million & CAGR)
Figure 11: United States Endometriosis and Uterine Fibroids Market Absolute Opportunity, By Progesterone, 2020-2030 (USD Million)
Figure 12: United States Endometriosis and Uterine Fibroids Market Size, By GnRH Agonist, By Value, 2020H-2030F (USD Million & CAGR)
Figure 13: United States Endometriosis and Uterine Fibroids Market Absolute Opportunity, By GnRH Agonist, 2020-2030 (USD Million)
Figure 14: United States Endometriosis and Uterine Fibroids Market Size, By Others, By Value, 2020H-2030F (USD Million & CAGR)
Figure 15: United States Endometriosis and Uterine Fibroids Market Absolute Opportunity, By Others, 2020-2030 (USD Million)
Figure 16: Market Attractiveness Analysis of United States Endometriosis and Uterine Fibroid Market, By Route of Administration (2025-2030)
Figure 17: United States Endometriosis and Uterine Fibroids Market Size, By Oral, By Value, 2020H-2030F (USD Million & CAGR)
Figure 18: United States Endometriosis and Uterine Fibroids Market Absolute Opportunity, By Oral, 2020-2030 (USD Million)
Figure 19: United States Endometriosis and Uterine Fibroids Market Size, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)
Figure 20: United States Endometriosis and Uterine Fibroids Market Absolute Opportunity, By Parenteral, 2020-2030 (USD Million)
Figure 21: Market Attractiveness Analysis of United States Endometriosis and Uterine Fibroid Market, By Distribution Channel (2025-2030)
Figure 22: United States Endometriosis and Uterine Fibroids Market Size, By Hospital Pharmacies, By Value, 2020H-2030F (USD Million & CAGR)
Figure 23: United States Endometriosis and Uterine Fibroids Market Absolute Opportunity, By Hospital Pharmacies, 2020-2030 (USD Million)
Figure 24: United States Endometriosis and Uterine Fibroids Market Size, By Retail Pharmacies, By Value, 2020H-2030F (USD Million & CAGR)
Figure 25: United States Elevated Work Platform (Endometriosis and Uterine Fibroids) Market Absolute Opportunity, By Retail Pharmacies, 2020-2030 (USD Million)
Figure 26: United States Endometriosis and Uterine Fibroids Market Size, By Online Pharmacies, By Value, 2020H-2030F (USD Million & CAGR)
Figure 27: United States Elevated Work Platform (Endometriosis and Uterine Fibroids) Market Absolute Opportunity, By Online Pharmacies, 2020-2030 (USD Million)
Figure 28: Global Impact of Drivers and Restraints
Figure 29: Market Share of Prominent Companies of United States Endometriosis and Uterine Fibroids Market, 2023 (%)
Figure 30: AbbVie Inc. Revenue, 2021-2023 (USD Million)
Figure 31: AbbVie Inc. Revenue, By Geographical Segments, 2023 (%)
Figure 32: AbbVie Inc. Revenue, By Business Segments, 2023 (%)
Figure 33: Pfizer Inc. Revenue, 2021-2023 (USD Million)
Figure 34: Pfizer Inc. Revenue, By Geographical Segments, 2023 (%)
Figure 35: Pfizer Inc. Revenue, By Business Segments, 2023 (%)
Figure 36: AstraZeneca plc. Revenue, 2021-2023 (USD Million)
Figure 37: AstraZeneca plc. Revenue, By Geographical Segments, 2023 (%)
Figure 38: AstraZeneca plc. Revenue, By Business Segments, 2023 (%)
Figure 39: Glenmark Revenue, 2021-2023 (USD Million)
Figure 40: Glenmark Revenue, By Geographical Segments, 2023 (%)
Figure 41: Glenmark Revenue, By Business Segments, 2023 (%)
Figure 42: Aspen Pharmaceuticals Revenue, 2021-2023 (USD Million)
Figure 43: Aspen Pharmaceuticals Revenue, By Geographical Segments, 2023 (%)
Figure 44: Aspen Pharmaceuticals Revenue, By Business Segments, 2023 (%)
Figure 45: Agile Therapeutics Inc Revenue, 2021-2023 (USD Million)
Figure 46: Cipla Ltd. Revenue, 2021-2023 (USD Million)
Figure 47: Cipla Ltd. Revenue, By Geographical Segments, 2023 (%)
Figure 48: Cipla Ltd. Revenue, By Business Segments, 2023 (%)
Figure 49: Takeda Revenue, 2021-2023 (USD Million)
Figure 50: Takeda Revenue, By Geographical Segments, 2023 (%)
Figure 51: Takeda Revenue, By Business Segments, 2023 (%)

List of Tables

Table A1: Global Impact of Macro Economic Factors, By Region
Table A2: Endometriosis Drugs in Pipeline
Table A3: Uterine Fibroids Drugs in Pipeline
Table A4: AbbVie Inc. Key Company Financials, 2021-2023
Table A5: Pfizer Inc. Key Company Financials, 2021-2023
Table A6: AstraZeneca plc. Key Company Financials, 2021-2023
Table A7: Glenmark Key Company Financials, 2021-2023
Table A8: Aspen Pharmaceuticals Key Company Financials, 2021-2023
Table A9: Agile Therapeutics Inc. Key Company Financials, 2021-2023
Table A10: Cipla Ltd. Key Company Financials, 2021-2023
Table A11: Takeda Key Company Financials, 2021-2023